Novonesis Takes Full Ownership of MicroBioGen as Yeast Deal Clears Regulators

Danish biosolutions company Novonesis has completed the acquisition of MicroBioGen, a Sydney-based yeast strain developer that it first invested in back in 2013. The deal was finalized after receiving all necessary regulatory approvals, including those from the Australian Competition and Consumer Commission. This acquisition allows Novonesis to fully own MicroBioGen, where previously they held a 23% stake, and strengthens their yeast capabilities for various industries.

MicroBioGen, which was spun out of Macquarie University in 2001, has developed a library of Saccharomyces cerevisiae genetics primarily focused on bioethanol production. Novonesis plans to expand the use of this technology beyond ethanol production, exploring applications in biochemicals, feed, and food industries. By combining their expertise and technologies, the companies aim to develop new biosolutions to meet the needs of their customers across multiple sectors.

Novonesis, formed through the merger of Novozymes and Chr. Hansen, views the acquisition of MicroBioGen as a strategic move to advance their 2030 plan by enhancing their yeast capabilities and expanding their research and development expertise. The acquisition reflects their commitment to investing in growth and supporting existing collaborations and partnerships.